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Abstract
Antimicrobial resistance (AMR) is an emerging threat to modern medicine. Improved diagnostics and surveillance of resistant 
bacteria require the development of next- generation analysis tools and collaboration between international partners. Here, we 
present the ‘AMR Data Hub’, an online infrastructure for storage and sharing of structured phenotypic AMR data linked to bacte-
rial whole- genome sequences. Leveraging infrastructure built by the European COMPARE Consortium and structured around 
the European Nucleotide Archive (ENA), the AMR Data Hub already provides an extensive data collection of more than 2500 
isolates with linked genome and AMR data. Representing these data in standardized formats, we provide tools for the validation 
and submission of new data and services supporting search, browse and retrieval. The current collection was created through 
a collaboration by several partners from the European COMPARE Consortium, demonstrating the capacities and utility of the 
AMR Data Hub and its associated tools. We anticipate growth of content and offer the hub as a basis for future research into 
methods to explore and predict AMR.
DATA SUMMARy
1. All scripts, antibiogram templates and tools (including 
validation and upload) created for this project are deposited 
in a public GitHub repository for easy access: https:// github. 
com/ EBI- COMMUNITY/ compare- amr
2. No new sequences were generated specifically for this 
project. All new antibiograms created for this project have 
been deposited in the AMR Data Hub. All data used in the 
AMR Data Hub is publicly available after the completion of 
the project and can be accessed via the Project- specific pages 
in the ENA browser. The AMR data containing projects are 
listed under ‘dcc_schubert’ here: https://www. ebi. ac. uk/ ena/ 
pathogens/ datahubs
3. The European Committee on Antimicrobial Susceptibility 
testing (EUCAST) maintains a database of MIC and zone 
diameter distributions with their respective ecological cut- 
off (ECOFF) values for a wide range of micro- organisms 
and antimicrobial agents. The E. coli ciprofloxacin resistance 
values were used for comparison with values deposited in the 
AMR Data Hub: https:// mic. eucast. org/ Eucast2/
4. Project PRJEB14981 conducted by the National Food Insti-
tute, Technical University of Denmark describes the genomes 
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and associated antibiograms of two cases of extremely drug- 
resistant Salmonella enterica serovar Senftenberg isolated 
from patients in Zambia. This project is used as an example 
of association of bacterial genomes and antibiogram using the 
AMR Data Hub architecture described in this report: https://
www. ebi. ac. uk/ ena/ browser/ view/ PRJEB14981
INTRODUCTION
Antimicrobials are widely regarded as one of the major 
advances in modern medicine [1]. The global emergence, 
however, of antimicrobial resistance (AMR) threatens the 
very core of modern medicine with the potential to turn the 
global population back in time to the pre- antibiotic era in 
which simple surgical procedures and common infections 
could have deadly consequences [2].
The decreased costs of next- generation sequencing (NGS) 
combined with the progress made in big data analysis such 
as machine learning (ML) represent innovative opportuni-
ties to tackle the AMR crisis [3]. Many bacterial phenotypic 
traits, including AMR, can be directly linked to the presence 
of genomic determinants such as genes, single nucleotide 
polymorphisms (SNPs) or transcription promoters, which 
can be identified using functional genomics approaches on 
large databases of genomes. AMR mechanisms are often 
multifactorial, which is a complicating factor for prediction. 
In order to circumvent the limitations of the traditional 
AMR gene presence/absence detection, methods using large 
amounts of data and unguided analysis of the whole bacterial 
genome are required. In this vein, recent studies have used 
computational approaches such as ML to predict antimicro-
bial susceptibility from genomic data or to discover previously 
unidentified antibiotic resistance determinants [4–6]. Today, 
the major limitation for such approaches is not the lack of 
advanced computational methods or hardware resources but 
the lack of large enough well curated, annotated data sets 
where phenotypic AMR data and genomes are linked.
Academic research initiatives and public health organisations 
could benefit from the implementation of online reposito-
ries capable of storing large amounts of genome sequence 
and antimicrobial susceptibility testing (AST) data [7]. For 
example, the PATRIC database (https:// patricbrc. org/ [6]) has 
been used for the development of AMR prediction algorithms, 
but is a closed system which does not support direct access 
and sharing with other major online genome repositories. 
The NCBI is offering a similar service, linking antibiograms 
with genomes deposited in the Sequence Repository Archive 
(SRA), but lacks a pre- publication data sharing mechanism 
for stakeholders within a given project (https://www. ncbi. 
nlm. nih. gov/ pathogens/ isolates#/ search/).
Different stakeholders in the AMR field have different 
requirements regarding the accessibility of AST data. Making 
optimal use of the opportunities described above requires 
enabling the global sharing of data, but some institutions 
are reluctant to immediately make their AST data publicly 
accessible for privacy, legal or other reasons [8]. National 
public health institutes would be encouraged to create supra- 
national networks using a standard format to share data for 
AST result analysis, while academics would find a solution 
to share post- publication data, encouraging reproducibility 
and cross- validation experiments, if such a database structure 
would become available. Thus, we have identified a clear need 
for a database structure that can support public AST data as 
well as those data that are to be shared privately for a period 
of time until publication.
The Horizon 2020 funded EU consortium COMPARE 
aims at bringing NGS to public health and clinical practice 
(http://www. compare- europe. eu/). European experts in AMR 
working within the COMPARE consortium, including the 
European Bioinformatics Institute (EMBL- EBI), which is part 
of the International Nucleotide Sequence Database Collabo-
ration (INSDC: http://www. insdc. org/), have deployed the 
‘Data Hub’ system to allow pre- publication sharing of isolate 
NGS and linked phenotypic AMR data. The Data Hub system 
provides a platform that allows data providers, such as public 
health and clinical laboratories, food safety agencies and 
veterinary institutes, consented sharing and download of 
genomic and related data sets. Data can either be kept private 
Impact Statement
Antimicrobial resistance is recognized as a major threat 
to modern medicine and needs new and improved 
methods for detection and surveillance. Whole- genome 
sequencing and subsequent bioinformatics analysis of 
resistant isolates are highly effective methods for identi-
fication of AMR markers and surveillance of their spread 
worldwide. However, further development in this field 
requires large amounts of genomic and phenotypical 
data, which will need to be stored and shared using reli-
able tools and infrastructure. In order to solve this issue 
the EU- H2020 funded COMPARE consortium has initi-
ated the ‘AMR Data Hub’, an online infrastructure built 
around the European Nucleotide Archive for storage 
and sharing of structured phenotypic AMR data linked 
to bacterial genome sequences. We describe the struc-
ture of this repository, its integration within the European 
Nucleotide Archive, the standardized antibiogram form 
used to provide AMR metadata to accompany genome 
sequences, and a collection of tools for preparation, 
retrieval and visualization of the data. An example of the 
data contained in the Data Hub is presented and its func-
tionalities are compared with other existing platforms 
such as the NCBI BioSample database. In particular, this 
new architecture allows the creation of private Data Hubs 
that can be used for sharing data among members of a 
specific project. This is critical when working with sensi-
tive data (patients, public health or surveillance records). 
The data is finally publicly released after publication of 
the results.
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for a limited time (pre- publication) or released as open- access 
immediately at the discretion of the data providers [9], but 
regardless of the data status (pre- publication private or 
public) all data can be linked to a Data Hub where it can 
be accessed by consumers who have been given consent by 
data providers. The data can be downloaded and analysed by 
the stakeholders or run through analysis pipelines that are 
available through the COMPARE platform [9] that is linked 
to the Data Hubs, and finally analysis results can also be fed 
back into the Data Hubs and be made available to users of 
the Data Hub of interest. Novel software was developed for 
use in the AMR Data Hub that validates the conformity of 
submitted datasets. The system supports both qualitative 
and quantitative AST data such as those resulting from disk 
diffusion and micro- broth dilution tests. A system of Jupyter 
Notebooks allows for fast browsing and overview of the Data 
Hubs content.
Here, we present the AMR Data Hub, which permits sharing 
of large amounts of information that could be used for ML 
and other data analysis approaches, eventually resulting in 
accurate and quantitative, hence clinically relevant, predic-
tions of AMR phenotypes based on NGS data.
THe AMR DATA HUb
The Data Hub system
The COMPARE Data Hub system has been built as a broad 
infrastructure for the sharing and analysis of pathogen NGS 
data and related data types. Here is presented a brief outline 
of the relevant parts of the system while a full description 
is provided in Amid et al.[9]. The Data Hubs are provided 
upon the foundation of the European Nucleotide Archive 
(ENA: https://www. ebi. ac. uk/ ena), an open repository for 
sequence and related data [10]. The concept was developed 
and introduced as a model for rapid sharing of data and 
analysis outputs in public and pre- publication confidential 
status within the COMPARE consortium. Data providers 
can choose to use an existing Data Hub or request the crea-
tion of a new one from the ENA, in which case they will also 
decide who are the authorized members of the project. Each 
Data Hub is configured for a specific project and its access is 
restricted (by login and password) to the authorized members 
of the project. These members can link data (sequence and 
metadata) previously deposited in the ENA database to the 
Data Hub. The data can be pre- publication confidential but 
accessed through a Data Hub by authorized users only and/
or be made publicly available (i.e. accessible by any user of the 
ENA). In case of private data linked to a Data Hub, it will be 
shared with all members of the project with authorized access 
but will remain hidden from other ENA users. Ultimately, all 
data archived in Data Hubs are released into the public domain 
(through the ENA) after a period defined by data owners, and 
at the latest at the time of publication in a manuscript. Data 
and metadata reported by data providers are submitted to the 
hubs through systematic processes supported by a number of 
tools. Subsequently, structured and accessioned data/meta-
data are available for sharing between data consumers who 
have received consent from data providers. The ENA system 
then serves at the same time as a database for sequence data 
and metadata and a repository for storage and browsing of 
results which can be queried through the Pathogen portal 
(https://www. ebi. ac. uk/ ena/ pathogens/ home).
The antibiogram
In order to represent AST data, a new analysis type, ‘anti-
biogram’, has been added to cater for this new ENA database 
object. This data type leverages the extensible ‘analysis object’ 
system, with the addition of a new class specifically for the 
storage of phenotypic AMR data, designated ‘AMR_ANTI-
BIOGRAM’ and is linked to sequence data as a metadata 
object. Antibiograms are treated as data objects within the 
system and are supported in data submission and access 
services. They can easily be associated with a Data Hub for 
specific projects. As a new data type, building this support has 
required the development of open software that is distributed 
publicly (https:// github. com/ EBI- COMMUNITY/ compare- 
amr) and used internally at EMBL- EBI for the validation and 
submission of incoming AST data.
We have aimed with the antibiogram for a format that is 
flexible, complete and compatible with the NCBI equiva-
lent, to allow for a future comprehensive antibiogram data 
exchange across INSDC. Minimum requirements include, 
for each combination of isolate/ antibiotic provided, INSDC 
Sample accession (SAM*); species; antibiotic name; antibiotic 
susceptibility testing standard; breakpoint version; antibiotic 
susceptibility test method; measurement; measurement 
units; measurement sign; susceptibility phenotype; and test 
platform. Any combination of bacterial species and antimi-
crobial is supported. Reported antimicrobial susceptibility 
can be measured by micro- broth dilution or zone diameter, 
all major testing platforms (Sensititre, VITEK and Phoenix) 
and standards (EUCAST or CLSI) are accepted. More 
uncommon methods can be added by using the free- text 
format of these sections. To help data providers, a detailed 
protocol explaining the preparation of the metadata form is 
presented on the GitHub repository of the project (https:// 
github. com/ EBI- COMMUNITY/ compare- amr) along with 
tools for batch creation of antibiograms from Excel files. An 
interactive web page allowing the manual creation of anti-
biograms is in preparation. It will provide an easy alternative 
for data providers registering a limited number of samples. 
Finally, a tutorial explaining the steps required to retrieve data 
(genomes and antibiograms) from the datahub is available on 
the GitHub repository.
Each antibiogram is linked to a bacterial genome within ENA. 
The association is asserted by linking the analysis object, i.e. 
the antibiogram, with the corresponding study, example: 
https://www. ebi. ac. uk/ ena/ browser/ view/ PRJEB14981. As 
with other data deposited in the ENA, antibiograms can be 
kept confidential for a provider- defined period but must 
ultimately be released at the same time of publishing the 
associated genomic data into public view. Antibiograms 
can be queried and retrieved through the AMR Data Hub 
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Fig. 1. Visualization of the AST data deposited in the database on 03/12/2019. Data were filtered for: ciprofloxacin (antibiotic_name); E. 
coli (scientific_name) and mg l−1 (measurement_units). The numbers in each table cell represent the number of isolates from the given 
country with the given measurement value. Whole- genome- sequencing data are available for all isolates.
(while confidential) as well as (when made public) through 
other alternatives, such as the Pathogen Portal (https://www. 
ebi. ac. uk/ ena/ pathogens/ home), a Discovery Application 
Programming Interface (API: https://www. ebi. ac. uk/ ena/ 
portal/ api/), the ENA browser (https://www. ebi. ac. uk/ ena) 
and services providing high- volume data access such as the 
ENA File Downloader (https:// github. com/ enasequence/ ena- 
ftp- downloader/). Using the Pathogen Portal or the Portal 
API, various filters can be used to refine the query such 
as bacterial species, country of origin, host, and more. An 
authenticated user can access confidential and public data 
comprehensively across all authorized Data Hubs and public 
data not connected to Data Hubs.
Visualization tools
To visualize the contents of the AMR Data Hub, a Notebook 
was configured (Fig. 1) that has several options for compar-
ison of a defined set of parameters from the database, such 
as the distribution of the MIC of different antimicrobials as a 
function of the country of origin, or the comparison of MIC 
distributions between different antimicrobials. As such, this 
functionality can be used for surveillance purposes, providing 
a rapid overview of MIC distribution for a specific collection 
of isolates and how this compares to isolates from the same 
host or from different geographical regions.
The Notebook is integrated into the Pathogen Portal and 
can be accessed from https://www. ebi. ac. uk/ ena/ pathogens/ 
home. While analysing the data hosted in the AMR Data 
Hub, access to private data sets as well access to the Notebook 
results requires authentication via login and password with 
authorization to the corresponding project. In the meantime, 
all genomic data, associated AST and visualization results are 
publicly available via the Pathogen Portal under the ‘Explore’ 
tab. While the Notebook report to dcc_schubert (name of 
the AMR Data Hub), with views such as Fig. 1 and more, 
is directly available from the above link, the genomic data 
and associated AST can be accessed either via the respective 
project pages in ENA (see dcc_schubert: https://www. ebi. ac. 
uk/ ena/ pathogens/ datahubs), or by using the ‘Search’ option 
in the Pathogen Portal (https://www. ebi. ac. uk/ ena/ pathogens/ 
search), selecting ‘Data type: analysis’ and tailoring the search 
to find all analysis records of type ‘AMR_ANTIBIOGRAM’.
CURReNT CONTeNT
As of 03-12-2019 the AMR Data Hub contains 824 Escheri-
chia coli genomes with attached AST data, 1839 Salmonella 
enterica and 29 Enterococcus faecium originating from ten 
different countries. Data on susceptibility against 59 different 
antibiotics (or combinations) have been entered in the data-
base so far. As an example, 824 E. coli isolates originating 
from seven different countries (Bangladesh; Denmark; Italy; 
Netherlands; UK; USA; Japan; and Vietnam) have been tested 
for ciprofloxacin susceptibility, 721 by various dilution- based 
methods and 103 by disk diffusion. All the data listed here 
were shared privately by COMPARE partners or were publicly 
available in the ENA.
A total of 471 E. coli antibiograms were submitted directly 
by COMPARE partners, 247 by an external partner (Toho 
University School of Medicine, Japan) while 106 were 
imported from the US CDC database (n=30) or previous 
publications (n=76) [11, 12].
In order to accurately predict MICs from genomic data, the 
database used for machine- learning training should represent 
as accurately as possible the distribution of susceptibility levels 
expected in clinically relevant bacterial isolates. The EUCAST 
database (https:// mic. eucast. org/ Eucast2/) comprises more 
than 15 000 ciprofloxacin MIC values for E. coli. We compared 
the distribution of MICs in the EUCAST database and AMR 
Data Hub (Fig. 2, Table S1, available in the online version of 
this article).
In the AMR Data Hub set three distinct peaks can be observed 
at 0.016, 0.25 and 32 mg l−1. The distribution of MICs in the 
EUCAST database is slightly different, with a less pronounced 
peak at 0.25 mg l−1 (3.6 % of isolates at 0.25 mg l−1, 3.4 % at 
0.125 mg l−1 1.2 % at 0.5 mg l−1). Additionally high MIC values 
seem to be more abundant in the AMR Data Hub and low 
MICs in the EUCAST database. In particular no values below 
0.016 mg l−1 are recorded in the AMR Data Hub, probably 
reflecting the fact that the genomes of highly susceptible 
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Fig. 2. Proportion of MICs in mg l−1 for ciprofloxacin in E. coli in EUCAST 
and AMR Data Hub databases. See Table S1 for the absolute number 
of isolates.
isolates are rarely sequenced. Similarly, no values above 
64 mg l−1 are recorded. A Kolmogorov–Smirnov test showed 
that the distributions are indeed not similar (P<0.01). More 
effort should be directed towards increasing the availability 
of whole- genome sequencing of highly susceptible and to a 
lesser extent highly resistant E. coli isolates.
DISCUSSION
We have built the AMR Data Hub with the aim to provide 
a system for public health, food and veterinary institutes, 
clinical laboratories and researchers to share their genomic 
and related AST data. It can be used for standardized open- 
access data sharing, for example for published data, thus 
creating an ever- growing source of AST metadata available to 
researchers worldwide. The large volume of data made avail-
able will make it easier to use advanced statistical methods 
such as machine- learning to predict AMR phenotypes from 
genomic data and discover new AMR determinants as was 
recently demonstrated [13].
It has been recently underlined that application of the Nagoya 
Protocol, which regulates material and data sharing, to 
genetic information might threaten the timely sharing of data 
in times of public health emergencies [14]. In allowing the 
organization and sharing of linked genomics and AST data, 
the AMR Data Hub promotes openness and accessibility for 
these important data types while at the same time meeting the 
privacy concerns for pre- publication data. Considering the 
exponential rise in the number of bacterial genomes available, 
and the threat to modern medicine represented by the rise 
of AMR, the establishment of an AMR Data Hub that can 
address these privacy concerns, represents a timely effort to 
improve collaboration in this field.
The design of a standard data submission format benefited 
from the expertise of the COMPARE consortium, a group of 
international experts in bacterial genomics and AMR surveil-
lance and research. It is designed to be as exhaustive, and at 
the same time as flexible as possible to ensure easy sharing of 
AST data. The database is hosted at the EMBL- EBI, ensuring 
its connection to the world’s largest online repository of 
bacterial genomes. This system is also part of the ELIXIR 
infrastructure for sustainable maintenance in the future [15].
As members of the INSDC, EMBL- EBI and NCBI are part 
of a joined effort for standardization and sharing of genomic 
data. The NCBI can also host antibiograms in a similar format 
to that presented here, and efforts are currently ongoing to 
allow automated synchronization of content from both sides. 
This will greatly increase the flexibility and the reach of the 
AMR Data Hub. At the time of writing (3 December 2019) 
the NCBI BioSample collection contains 12 234 genomes 
with associated antibiograms compared to 2695 in the EBI 
AMR Data Hub. However, while NCBI does not provide a 
platform for pre- publication data sharing, the COMPARE 
Data Hubs [9] hosted at the EMBL- EBI support this model 
as a mean for rapid data sharing and analysis prior to publica-
tion. Participating institutions can thus choose whether they 
want their data to be open- access immediately or whether 
they prefer sharing it with selected members of a consortium 
before public release. This service is unique and could help 
data providers from public health and clinical laboratories, 
food safety agencies and veterinary institutes to overcome 
barriers of data sharing
The view is that the AMR Data Hub will soon become an 
essential resource for functional genomic studies of AMR. 
By encouraging data providers from different fields and 
geographical origins to share their data, this collection can 
greatly improve our ability to answer questions related to the 
current AMR crisis.
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